Mr. Ali Hedayat reports

DRI HEALTHCARE ANNOUNCES RECEIPT OF PUT PRICE ON EKTERLY

DRI Healthcare Trust has received the put price of approximately $178-million (U.S.) in connection with its previously announced exercise of the contractual put option with respect to its royalty participation right in Ekterly.

As previously announced on July 10, 2026, DRI Healthcare exercised the put option following the completion of Chiesi Group's acquisition of KalVista Pharmaceuticals, Inc. Receipt of the put price completes the transaction, and DRI Healthcare's royalty participation right in Ekterly has accordingly terminated.

"We are pleased to have completed the transaction and appreciate Chiesi's collaboration throughout the process," said Ali Hedayat, chief executive officer of DRI Healthcare. "This outcome reflects our disciplined underwriting and creates additional capacity to pursue attractive opportunities for our unitholders."

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, its deployed more than $3.0-billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga.

We seek Safe Harbor.